Aldeyra Therapeutics, Inc. (ALDX) News
Filter ALDX News Items
ALDX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALDX News Highlights
- For ALDX, its 30 day story count is now at 5.
- Over the past 14 days, the trend for ALDX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ALDX are TOP, ESP and SMTC.
Latest ALDX News From Around the Web
Below are the latest news stories about ALDEYRA THERAPEUTICS INC that investors may wish to consider to help them evaluate ALDX as an investment opportunity.
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic DermatitisLEXINGTON, Mass., December 19, 2023--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced positive top-line results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in patients with atopic dermatitis. Relative to baseline, the clinical trial demonstrated statistically significant and clinically relevant improvement in investiga |
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic DermatitisLEXINGTON, Mass., December 18, 2023--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial of ADX‑629 in patients with atopic dermatitis. |
13 Hot Penny Stocks To Buy According to Hedge FundsIn this article, we will take a look at the 13 Hot Penny Stocks To Buy According to Hedge Funds. To see more hot penny stocks, go directly to 5 Hot Penny Stocks To Buy According to Hedge Funds. The overall market optimism helped by expectations that the Fed might start cutting interest rates in […] |
3 Stocks at the Forefront of Personalized Medicine TrendUnveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly |
Semtech (SMTC) to Release Q3 Earnings: What's in the Cards?Semtech's (SMTC) third-quarter fiscal 2024 results are expected to reflect solid momentum in the industrial market amid macroeconomic challenges. |
Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?Aldeyra Therapeutics (ALDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseLEXINGTON, Mass., November 27, 2023--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. Although no safety or manufacturing issues with reproxala |
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie. |
Why Are Stocks Up Today?Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates. |
Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize ReproxalapLEXINGTON, Mass., November 01, 2023--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that it has entered into an exclusive option agreement with AbbVie Inc. (AbbVie). |